PMID- 18336617
OWN - NLM
STAT- MEDLINE
DCOM- 20080724
LR  - 20080619
IS  - 1464-410X (Electronic)
IS  - 1464-4096 (Linking)
VI  - 102
IP  - 1
DP  - 2008 Jul
TI  - The longitudinal relationship between the systemic inflammatory response, 
      circulating T-lymphocytes, interleukin-6 and -10 in patients undergoing 
      immunotherapy for metastatic renal cancer.
PG  - 125-9
LID - 10.1111/j.1464-410X.2008.07466.x [doi]
AB  - OBJECTIVE: To examine the longitudinal relationship between the systemic 
      inflammatory response, circulating T-lymphocyte subpopulations, interleukin-6 and 
      -10 in patients undergoing immunotherapy for metastatic renal cancer, as the 
      inflammation-based Glasgow Prognostic Score (GPS) provides additional prognostic 
      information in patients with advanced renal cancer, but the basis of the 
      relationship between the systemic inflammatory response and poorer survival is 
      not clear, and nor is the effect of immunotherapy on related variables. PATIENTS 
      AND METHODS: The study included 23 patients with metastatic renal cancer and 
      starting immunotherapy. Samples of blood were drawn for routine laboratory 
      analysis and to quantify cytokines using enzyme-linked immunosorbent assays 
      before immunotherapy, and repeated after 2 weeks of treatment. RESULTS: Most 
      patients had a good performance status, favourable or intermediate Memorial 
      Sloane-Kettering Cancer Center (MSKCC) risk scores, and with elevated C-reactive 
      protein (>10 mg/L), GPS (1 or 2), interleukin-6 (>4 pg/mL) and interleukin-10 
      (>10 pg/mL). Patients who completed one cycle of immunotherapy were more likely 
      to have a normal MSKCC (P < 0.05) or GPS (P < 0.05) scores, whilst the percentage 
      of lymphocytes was lower (P < 0.05). The MSKCC and the GPS scores did not alter 
      significantly during one cycle of immunotherapy. Similarly, leukocyte counts, 
      CD4+ and CD8+ T-lymphocytes, interleukin-6 and -10 concentrations did not change 
      significantly. CONCLUSIONS: The pretreatment systemic inflammatory response and 
      its related lymphopenia are important in determining the tolerance to 
      immunotherapy in patients with metastatic renal cancer. Immunotherapy is not 
      associated with changes in circulating T-lymphocytes, nor the systemic 
      inflammatory response.
FAU - Ramsey, Sara
AU  - Ramsey S
AD  - Department of Urology, Gartnavel General Hospital, Glasgow, Scotland, UK. 
      sara_l_ramsey@ntlworld.com
FAU - Aitchison, Michael
AU  - Aitchison M
FAU - Graham, John
AU  - Graham J
FAU - McMillan, Donald C
AU  - McMillan DC
LA  - eng
PT  - Journal Article
DEP - 20080311
PL  - England
TA  - BJU Int
JT  - BJU international
JID - 100886721
RN  - 0 (Albumins)
RN  - 0 (Interleukin-6)
RN  - 130068-27-8 (Interleukin-10)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Albumins/metabolism
MH  - C-Reactive Protein/metabolism
MH  - Carcinoma, Renal Cell/*immunology/therapy
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - *Immunotherapy
MH  - Interleukin-10/metabolism
MH  - Interleukin-6/metabolism
MH  - Kidney Neoplasms/*immunology/therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Prognosis
MH  - Systemic Inflammatory Response Syndrome/*immunology
MH  - T-Lymphocytes/*metabolism
EDAT- 2008/03/14 09:00
MHDA- 2008/07/25 09:00
CRDT- 2008/03/14 09:00
PHST- 2008/03/14 09:00 [pubmed]
PHST- 2008/07/25 09:00 [medline]
PHST- 2008/03/14 09:00 [entrez]
AID - BJU7466 [pii]
AID - 10.1111/j.1464-410X.2008.07466.x [doi]
PST - ppublish
SO  - BJU Int. 2008 Jul;102(1):125-9. doi: 10.1111/j.1464-410X.2008.07466.x. Epub 2008 
      Mar 11.